> Detailanzeige

Brastianos, Priscilla Kaliopi; Dooley, Katharine; Geyer, Susan Michelle; Gerstner, Elizabeth R; Kaufmann, Timothy J.; Iafrate, A. John; Milhem, Mohammed M.; Welch, Mary Roberta; Kaley, Thomas Joseph; Drappatz, Jan; Chan, Amy; Kumthekar, Priya; Kamiya-Matsuoka, Carlos; Strowd, Roy E.; Cohen, Adam Louis; Jaeckle, Kurt A.; Robell, Lindsay; Santagata, Sandro; Barker, Frederick G.; Galanis, Evanthia

Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations
  • Beteiligte: Brastianos, Priscilla Kaliopi; Dooley, Katharine; Geyer, Susan Michelle; Gerstner, Elizabeth R; Kaufmann, Timothy J.; Iafrate, A. John; Milhem, Mohammed M.; Welch, Mary Roberta; Kaley, Thomas Joseph; Drappatz, Jan; Chan, Amy; Kumthekar, Priya; Kamiya-Matsuoka, Carlos; Strowd, Roy E.; Cohen, Adam Louis; Jaeckle, Kurt A.; Robell, Lindsay; Santagata, Sandro; Barker, Frederick G.; Galanis, Evanthia
  • Erschienen: American Society of Clinical Oncology (ASCO), 2024
  • Erschienen in: Journal of Clinical Oncology, 42 (2024) 16_suppl, Seite 2001-2001
  • Sprache: Englisch
  • DOI: 10.1200/jco.2024.42.16_suppl.2001
  • ISSN: 1527-7755; 0732-183X
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: 2001 Background: Systemic treatments are limited for patients with meningiomas that have progressed after surgery and/or radiation. Loss of NF2and CDKN2A/Bare common in higher grade meningiomas and promote meningioma progression in preclinical models. We evaluated the efficacy of abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, as part of Alliance umbrella trial A071401, a genomically driven phase II study in recurrent or progressive meningiomas. Methods: Eligible patients (pts) with grade 2/3 tumors and NF2 mutations or CDK pathway alterations were treated with abemaciclib 200 mg orally twice daily until progressive disease. Two co-primary endpoints were used: progression-free survival at 6 months (PFS6) and response rate (RR) by Macdonald criteria; the trial would be declared positive if either endpoint was met. Twenty-four evaluable pts provided >85% power to detect a PFS6 >41.5% (vs. null 15%; alpha =0.02). The threshold for promising results for PFS6 was 8+/24 pts. For RR, 24 evaluable pts provided >89% power to detect RR >20% (vs. null 2.5%; alpha = 0.021). The threshold for promising results for RR was 3+/24 pts. Results: Of 83 pts screened while the abemaciclib arm was open between September 15, 2021 and October 3, 2022, 36 eligible pts received treatment. The mean number of treatment cycles administered was 7 and median follow-up since start of treatment was 11 months. The first 24 pts that met eligibility criteria and began treatment were considered evaluable for the primary endpoint analysis. Of the 24 pts evaluated, 58% were female and the median age was 62 years. The observed PFS6 rate was 54% (13/24 pts, 95% confidence interval 33-75%), thus the study met PFS6 endpoint. No objective responses were observed. Of the 36 pts who started treatment, eight had a grade 3 and two had a grade 4 adverse event at least possibly related to treatment. Grade 3 toxicities included anemia (2), neutropenia (2), leukopenia (1), blurry vision (1), diarrhea (2), fatigue (2), ALT elevation (1), dehydration (1), hyperkalemia (1), hyponatremia (1), dizziness (1), acute kidney injury (1), and thromboembolic event (1). Grade 4 toxicities included ALT elevation (1), AST elevation (1) and vomiting (1). Conclusions: Abemaciclib was well tolerated and resulted in an improved PFS6. The overall trial endpoint was met. Abemaciclib warrants further investigation for the treatment of patients with progressive grade 2/3 meningiomas. Support: U10CA180821, U10CA180882; UG1CA189867 (NRG Oncology); Eli Lilly; https://acknowledgments.alliancefound.org . Clinical trial information: NCT02523014 .